Clinical Trials Browser

Gemcitabine × Genitourinary × 30 days × Clear all

NCT04658862 2026-06-05

SunRISe-2

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT06211764 2026-06-05

SunRISe-5

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-06-05

MoonRISe-1

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-06-05

MoonRISe-3

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

Renal Pelvis and Ureter Urothelial Carcinoma

NCT06770582 2026-06-03

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT07000084 2026-06-02

GAIN-BCG

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04223856 2026-05-29

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT04579224 2026-05-29

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06388720 2026-05-29

IMGeS

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03682068 2026-05-28

NILE

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03924856 2026-05-28

KEYNOTE-866

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT06972615 2026-05-28

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT07608224 2026-05-27

HOPE-07-MIBC

Phase 2/3 Not yet recruiting

Urinary Bladder Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT06545955 2026-05-22

ABLE-22

Phase 3 Recruiting

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT03093909 2026-05-20

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Phase 1 Recruiting

DermatologicGenitourinarySarcoma

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Phase EARLY_PHASE1 Enrolling by invitation

Muscle Invasive Bladder Urothelial Carcinoma